Melissa Hakula

Melissa Hakula, the FT's AI correspondent, and Eleanor Alcott, covering China's biopharma sector, delve into fierce competition in the AI chatbot race, highlighting Mistral's innovative models challenging OpenAI. They discuss the implications of OpenAI's 'code red' alert due to emerging rivals and explore the rapid rise of China's biotech industry, driven by government support and efficient clinical trials. The conversation also speculates on whether Chinese biotechs will dominate globally or forge ties with Western companies.